AID Partners Acquires GenseSort, for $23M

GeneSort, a Herzliya, Israel-based medical diagnostic company, is being acquired by Hong Kong-based investment group AID Partners, for $23m.

The deal will support GeneSort in its expansion into southeast Asia and other global markets.

Led by Dr. Gil Pogozelich, Chairman and CEO, GeneSort is a medical diagnostic company that has created technology that identifies genetic mutations related to specific cancers, helping doctors recommend personalized and targeted treatment strategies.
The company has recently signed a development contract with the government of Malta, as well as with the Israeli government to deploy diagnostic testing in the country.

The lead investor in GeneSort was Singulariteam.



Join the discussion